{"id":"https://openalex.org/W7215195337","doi":null,"title":"FGF21 Contributes to Metabolic Improvements Elicited by Exenatide and Pioglitazone in Patients with Type 2 Diabetes","display_name":"FGF21 Contributes to Metabolic Improvements Elicited by Exenatide and Pioglitazone in Patients with Type 2 Diabetes","publication_year":2022,"publication_date":"2022-01-01","ids":{"openalex":"https://openalex.org/W7215195337"},"language":"en","primary_location":{"id":"pmh:oai:erepo.uef.fi:123456789/28802","doi":null,"is_oa":true,"landing_page_url":"https://erepo.uef.fi/handle/123456789/28802","pdf_url":"https://erepo.uef.fi/bitstreams/4c5c8b2a-3f0e-411d-b4bf-a530c4172d87/download","source":{"id":"https://openalex.org/S4306402418","display_name":"UEF eRepo (University of Eastern Finland)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I175532246","host_organization_name":"University of Eastern Finland","host_organization_lineage":["https://openalex.org/I175532246"],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"info:eu-repo/semantics/article"},"volume":null,"type":"article","indexed_in":[],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://erepo.uef.fi/bitstreams/4c5c8b2a-3f0e-411d-b4bf-a530c4172d87/download","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5061640534","display_name":"Ricardo J. Samms","orcid":"https://orcid.org/0000-0001-9138-3091","observed_orcids":["https://orcid.org/0000-0001-9138-3091"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Samms, Ricardo J","raw_affiliation_strings":["Eli Lilly and Company ;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company ;","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113691364","display_name":"Christine C. Cheng","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Cheng, Christine C","raw_affiliation_strings":["Eli Lilly and Company ;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company ;","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008072277","display_name":"Marcel J. Fourcaudot","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I165951966","display_name":"The University of Texas at San Antonio Health Science Center","ror":"https://ror.org/02f6dcw23","country_code":"US","type":"education","lineage":["https://openalex.org/I165951966","https://openalex.org/I45438204"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Fourcaudot, Marcel","raw_affiliation_strings":["Diabetes Division , University of Texas Health San Antonio , TX ;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Diabetes Division , University of Texas Health San Antonio , TX ;","institution_ids":["https://openalex.org/I165951966"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069483577","display_name":"Sami Heikkinen","orcid":"https://orcid.org/0000-0002-6083-2402","observed_orcids":["https://orcid.org/0000-0002-6083-2402"]},"institutions":[{"id":"https://openalex.org/I175532246","display_name":"University of Eastern Finland","ror":"https://ror.org/00cyydd11","country_code":"FI","type":"education","lineage":["https://openalex.org/I175532246"]}],"countries":["FI"],"is_corresponding":false,"raw_author_name":"Heikkinen, Sami","raw_affiliation_strings":["Institute of Biomedicine , University of Eastern Finland , Kuopio , Finland;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Institute of Biomedicine , University of Eastern Finland , Kuopio , Finland;","institution_ids":["https://openalex.org/I175532246"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5153972212","display_name":"Ahmed Khattab","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I165951966","display_name":"The University of Texas at San Antonio Health Science Center","ror":"https://ror.org/02f6dcw23","country_code":"US","type":"education","lineage":["https://openalex.org/I165951966","https://openalex.org/I45438204"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Khattab, Ahmed","raw_affiliation_strings":["Diabetes Division , University of Texas Health San Antonio , TX ;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Diabetes Division , University of Texas Health San Antonio , TX ;","institution_ids":["https://openalex.org/I165951966"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5153947930","display_name":"John Adams","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I165951966","display_name":"The University of Texas at San Antonio Health Science Center","ror":"https://ror.org/02f6dcw23","country_code":"US","type":"education","lineage":["https://openalex.org/I165951966","https://openalex.org/I45438204"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Adams, John","raw_affiliation_strings":["Diabetes Division , University of Texas Health San Antonio , TX ;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Diabetes Division , University of Texas Health San Antonio , TX ;","institution_ids":["https://openalex.org/I165951966"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079024626","display_name":"Eug\u00eanio Cers\u00f3simo","orcid":"https://orcid.org/0000-0002-2573-0208","observed_orcids":["https://orcid.org/0000-0002-2573-0208"]},"institutions":[{"id":"https://openalex.org/I165951966","display_name":"The University of Texas at San Antonio Health Science Center","ror":"https://ror.org/02f6dcw23","country_code":"US","type":"education","lineage":["https://openalex.org/I165951966","https://openalex.org/I45438204"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Cersosimo, Eugenio","raw_affiliation_strings":["Diabetes Division , University of Texas Health San Antonio , TX ;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Diabetes Division , University of Texas Health San Antonio , TX ;","institution_ids":["https://openalex.org/I165951966"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083775716","display_name":"Curtis L. Triplitt","orcid":"https://orcid.org/0000-0002-7775-7816","observed_orcids":["https://orcid.org/0000-0002-7775-7816"]},"institutions":[{"id":"https://openalex.org/I165951966","display_name":"The University of Texas at San Antonio Health Science Center","ror":"https://ror.org/02f6dcw23","country_code":"US","type":"education","lineage":["https://openalex.org/I165951966","https://openalex.org/I45438204"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Triplitt, Curtis","raw_affiliation_strings":["Diabetes Division , University of Texas Health San Antonio , TX ;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Diabetes Division , University of Texas Health San Antonio , TX ;","institution_ids":["https://openalex.org/I165951966"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025821753","display_name":"CURTISS L. PUCKETT","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I165951966","display_name":"The University of Texas at San Antonio Health Science Center","ror":"https://ror.org/02f6dcw23","country_code":"US","type":"education","lineage":["https://openalex.org/I165951966","https://openalex.org/I45438204"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Puckett, Curtis","raw_affiliation_strings":["Diabetes Division , University of Texas Health San Antonio , TX ;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Diabetes Division , University of Texas Health San Antonio , TX ;","institution_ids":["https://openalex.org/I165951966"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002870987","display_name":"Kostas Tsintzas","orcid":"https://orcid.org/0000-0002-3405-5769","observed_orcids":["https://orcid.org/0000-0002-3405-5769"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Tsintzas, Kostas","raw_affiliation_strings":["School of Life Sciences ,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"School of Life Sciences ,","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5154265639","display_name":"Andrew Charles Adams","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Adams, Andrew Charles","raw_affiliation_strings":["Eli Lilly and Company ;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company ;","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005726509","display_name":"Muhammad A Abdul\u2010Ghani","orcid":"https://orcid.org/0000-0003-4556-1787","observed_orcids":["https://orcid.org/0000-0003-4556-1787","https://orcid.org/0000-0003-2165-695X"]},"institutions":[{"id":"https://openalex.org/I165951966","display_name":"The University of Texas at San Antonio Health Science Center","ror":"https://ror.org/02f6dcw23","country_code":"US","type":"education","lineage":["https://openalex.org/I165951966","https://openalex.org/I45438204"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Abdul-Ghani, Muhammad A","raw_affiliation_strings":["Diabetes Division , University of Texas Health San Antonio , TX ;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Diabetes Division , University of Texas Health San Antonio , TX ;","institution_ids":["https://openalex.org/I165951966"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073917506","display_name":"Ralph Anthony DeFronzo","orcid":"https://orcid.org/0000-0002-8581-6273","observed_orcids":["https://orcid.org/0000-0002-8581-6273"]},"institutions":[{"id":"https://openalex.org/I142263535","display_name":"University of Nottingham","ror":"https://ror.org/01ee9ar58","country_code":"GB","type":"education","lineage":["https://openalex.org/I142263535"]},{"id":"https://openalex.org/I165951966","display_name":"The University of Texas at San Antonio Health Science Center","ror":"https://ror.org/02f6dcw23","country_code":"US","type":"education","lineage":["https://openalex.org/I165951966","https://openalex.org/I45438204"]},{"id":"https://openalex.org/I4210137227","display_name":"Queen's Medical Centre","ror":"https://ror.org/03ap6wx93","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1334287468","https://openalex.org/I4210137227"]}],"countries":["GB","US"],"is_corresponding":false,"raw_author_name":"DeFronzo, Ralph A","raw_affiliation_strings":["Diabetes Division , University of Texas Health San Antonio , TX ;","Queen's Medical Centre , University of Nottingham , Nottingham , UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Diabetes Division , University of Texas Health San Antonio , TX ;","institution_ids":["https://openalex.org/I165951966"]},{"raw_affiliation_string":"Queen's Medical Centre , University of Nottingham , Nottingham , UK","institution_ids":["https://openalex.org/I142263535","https://openalex.org/I4210137227"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5041583991","display_name":"Luke Norton","orcid":"https://orcid.org/0000-0002-0231-5722","observed_orcids":["https://orcid.org/0000-0002-0231-5722"]},"institutions":[{"id":"https://openalex.org/I165951966","display_name":"The University of Texas at San Antonio Health Science Center","ror":"https://ror.org/02f6dcw23","country_code":"US","type":"education","lineage":["https://openalex.org/I165951966","https://openalex.org/I45438204"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Norton, Luke","raw_affiliation_strings":["Diabetes Division , University of Texas Health San Antonio , TX ;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Diabetes Division , University of Texas Health San Antonio , TX ;","institution_ids":["https://openalex.org/I165951966"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":5,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.25444531,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12287","display_name":"Fibroblast Growth Factor Research","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T12287","display_name":"Fibroblast Growth Factor Research","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.0012000000569969416,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10528","display_name":"Adipokines, Inflammation, and Metabolic Diseases","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2713","display_name":"Epidemiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/fgf21","display_name":"FGF21","score":0.9559999704360962},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.9959999918937683},{"id":"https://openalex.org/keywords/exenatide","display_name":"exenatide","score":0.9869999885559082},{"id":"https://openalex.org/keywords/pioglitazone","display_name":"pioglitazone","score":0.9980000257492065},{"id":"https://openalex.org/keywords/metformin","display_name":"metformin","score":0.9509999752044678},{"id":"https://openalex.org/keywords/triple-therapy","display_name":"triple therapy","score":0.9070000052452087},{"id":"https://openalex.org/keywords/insulin-sensitivity","display_name":"insulin sensitivity","score":0.7289999723434448},{"id":"https://openalex.org/keywords/beta-cell-function","display_name":"beta-cell function","score":0.9160000085830688},{"id":"https://openalex.org/keywords/glucose-tolerance","display_name":"glucose tolerance","score":0.9520000219345093},{"id":"https://openalex.org/keywords/glycemic-control","display_name":"glycemic control","score":0.6990000009536743}],"concepts":[{"id":"https://openalex.org/C106646824","wikidata":"https://www.wikidata.org/wiki/Q5425475","display_name":"FGF21","level":4,"score":0.9545000195503235},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.8216999769210815},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.8004000186920166},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.769599974155426},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.7366999983787537},{"id":"https://openalex.org/C2778384471","wikidata":"https://www.wikidata.org/wiki/Q417765","display_name":"Pioglitazone","level":4,"score":0.7196000218391418},{"id":"https://openalex.org/C2780533449","wikidata":"https://www.wikidata.org/wiki/Q417762","display_name":"Exenatide","level":4,"score":0.5586000084877014},{"id":"https://openalex.org/C2779306644","wikidata":"https://www.wikidata.org/wiki/Q2002370","display_name":"Insulin","level":2,"score":0.508899986743927},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.4805000126361847},{"id":"https://openalex.org/C2777391703","wikidata":"https://www.wikidata.org/wiki/Q1053470","display_name":"Insulin resistance","level":3,"score":0.35089999437332153},{"id":"https://openalex.org/C2780833929","wikidata":"https://www.wikidata.org/wiki/Q1501412","display_name":"Glucose tolerance test","level":4,"score":0.30709999799728394},{"id":"https://openalex.org/C193230392","wikidata":"https://www.wikidata.org/wiki/Q1663054","display_name":"Ingestion","level":2,"score":0.30059999227523804},{"id":"https://openalex.org/C2910068830","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 Diabetes Mellitus","level":3,"score":0.2800000011920929},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.2671000063419342},{"id":"https://openalex.org/C70818257","wikidata":"https://www.wikidata.org/wiki/Q502671","display_name":"Metabolic control analysis","level":3,"score":0.2574000060558319},{"id":"https://openalex.org/C2780578515","wikidata":"https://www.wikidata.org/wiki/Q657193","display_name":"Metabolic syndrome","level":3,"score":0.25049999356269836}],"mesh":[],"locations_count":1,"locations":[{"id":"pmh:oai:erepo.uef.fi:123456789/28802","doi":null,"is_oa":true,"landing_page_url":"https://erepo.uef.fi/handle/123456789/28802","pdf_url":"https://erepo.uef.fi/bitstreams/4c5c8b2a-3f0e-411d-b4bf-a530c4172d87/download","source":{"id":"https://openalex.org/S4306402418","display_name":"UEF eRepo (University of Eastern Finland)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I175532246","host_organization_name":"University of Eastern Finland","host_organization_lineage":["https://openalex.org/I175532246"],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":{"id":"pmh:oai:erepo.uef.fi:123456789/28802","doi":null,"is_oa":true,"landing_page_url":"https://erepo.uef.fi/handle/123456789/28802","pdf_url":"https://erepo.uef.fi/bitstreams/4c5c8b2a-3f0e-411d-b4bf-a530c4172d87/download","source":{"id":"https://openalex.org/S4306402418","display_name":"UEF eRepo (University of Eastern Finland)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I175532246","host_organization_name":"University of Eastern Finland","host_organization_lineage":["https://openalex.org/I175532246"],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"info:eu-repo/semantics/article"},"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320306089","display_name":"American Diabetes Association","ror":"https://ror.org/04f6cgz95"},{"id":"https://openalex.org/F4320307115","display_name":"Bristol-Myers Squibb","ror":"https://ror.org/00gtmwv55"},{"id":"https://openalex.org/F4320307758","display_name":"Eli Lilly and Company","ror":"https://ror.org/01qat3289"},{"id":"https://openalex.org/F4320307768","display_name":"Amylin Pharmaceuticals","ror":"https://ror.org/043cec594"},{"id":"https://openalex.org/F4320332161","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7215195337.pdf","grobid_xml":"https://content.openalex.org/works/W7215195337.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4283159662","https://openalex.org/W2389974717","https://openalex.org/W2921923411","https://openalex.org/W2312946897","https://openalex.org/W2150640537","https://openalex.org/W3121425505","https://openalex.org/W2157891550","https://openalex.org/W1978914376","https://openalex.org/W2031514101","https://openalex.org/W2373331847"],"abstract_inverted_index":{"Fibroblast":[0],"growth":[1],"factor":[2],"21":[3],"(FGF21)":[4],"is":[5,12],"increased":[6,26,140],"acutely":[7,150],"by":[8],"carbohydrate":[9],"ingestion":[10],"and":[11,90,102,107,114,135,161,224,242,268,273,292,297],"elevated":[13],"in":[14,28,122,129,154,168,179,189,205,213,228,244,277,287,312,322],"patients":[15,46,61,169,246,253,288,323],"with":[16,47,49,62,186,218,247,254,257,285,290,324],"type":[17],"2":[18],"diabetes":[19],"(T2D).":[20],"However,":[21],"the":[22,39,116,152,180,229,236,278,315],"physiological":[23],"significance":[24],"of":[25,45,94,182,220,240,260,280,295],"FGF21":[27,36,109,146,163,184,203,215,231,271,283,307],"humans":[29],"remains":[30],"largely":[31],"unknown.":[32],"We":[33],"examined":[34],"whether":[35],"contributed":[37],"to":[38,66,73,96,194,207,235,314],"metabolic":[40,238],"improvements":[41,128],"observed":[42,188,265,318],"following":[43,91,319],"treatment":[44,95,124,199],"T2D":[48,63,255],"either":[50,68],"triple":[51,69,142,171,197],"(metformin/pioglitazone/exenatide)":[52],"or":[53,70],"conventional":[54,71],"(metformin/insulin/glipizide)":[55],"therapy":[56,72,198,321],"for":[57],"3":[58,92],"yr.":[59],"Forty-six":[60],"were":[64,111,138,148,165,216],"randomized":[65],"receive":[67],"maintain":[74],"HbA1c":[75],"<":[76],"6.5%.":[77],"A":[78],"2-h":[79],"75-g":[80],"oral":[81],"glucose":[82,98,130,209,222],"tolerance":[83],"test":[84],"(OGTT)":[85],"was":[86,175],"performed":[87],"at":[88,118,310],"baseline":[89,195],"years":[93],"assess":[97],"tolerance,":[99],"insulin":[100,133,225,299],"sensitivity,":[101],"\u03b2-cell":[103,136],"function.":[104],"Plasma":[105],"total":[106,160,267],"bioactive":[108,162,183,269,282],"levels":[110,147,164,204,272],"quantitated":[112],"before":[113],"during":[115,151],"OGTT":[117,153],"both":[119,123,155],"visits.":[120],"Patients":[121],"arms":[125],"experienced":[126],"significant":[127],"control,":[131],"but":[132,173],"sensitivity":[134],"function":[137],"markedly":[139],"after":[141],"therapy.":[143],"At":[144],"baseline,":[145],"regulated":[149],"groups.":[156],"After":[157],"treatment,":[158],"fasting":[159],"significantly":[166,201],"reduced":[167,266],"receiving":[170],"therapy,":[172],"there":[174],"a":[176,208,258,274],"relative":[177,275],"increase":[178,276],"proportion":[181,279],"compared":[185,284],"that":[187,286,306],"conventionally":[190],"treated":[191,256,289],"subjects.":[192],"Relative":[193],"studies,":[196],"also":[200],"modified":[202],"response":[206],"load.":[210],"These":[211,303],"changes":[212],"circulating":[214,281],"correlated":[217],"markers":[219],"improved":[221],"control":[223],"sensitivity.":[226],"Alterations":[227],"plasma":[230,270],"profile":[232],"may":[233,308],"contribute":[234],"beneficial":[237],"effects":[239],"pioglitazone":[241],"exenatide":[243],"human":[245],"T2D.":[248,325],"NEW":[249],"&":[250],"NOTEWORTHY":[251],"In":[252],"combination":[259,320],"metformin/pioglitazone/exenatide":[261],"(triple":[262],"therapy),":[263],"we":[264],"metformin":[291],"sequential":[293],"addition":[294],"glipizide":[296],"basal":[298],"glargine":[300],"(conventional":[301],"therapy).":[302],"data":[304],"suggest":[305],"contribute,":[309],"least":[311],"part,":[313],"glycemic":[316],"benefits":[317]},"counts_by_year":[],"updated_date":"2026-10-26T11:51:55.731654","created_date":"2026-10-02T00:00:00"}